{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:39:32Z","timestamp":1782380372190,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T00:00:00Z","timestamp":1515456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clinthera.2017.12.018","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T01:10:20Z","timestamp":1518225020000},"page":"226-241.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin &amp; Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial"],"prefix":"10.1016","volume":"40","author":[{"given":"Soon Jun","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Saem","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Cheon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hun","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Heon","family":"Won","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kyoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Su","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Chul","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Woon","family":"Rha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Han","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoo Rok","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wook Sung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Su","family":"Hyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Cheol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jang-Ho","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moo-Yong","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Woon","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Dong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.12.018_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2017.12.018_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.02.027","article-title":"Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg\/dl or >\/= 50% reduction in high-risk patients: results from VOYAGER","volume":"228","author":"Karlson","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2017.12.018_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.12.018_bib4","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2217\/pgs.11.98","article-title":"Statin dose in Asians: is pharmacogenetics relevant?","volume":"12","author":"Wang","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2017.12.018_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cjca.2011.01.016","article-title":"Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary)","volume":"27","author":"Leiter","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.clinthera.2017.12.018_bib6","unstructured":"FDA Public Health Advisory for Crestor (rosuvastatin): US Food and Drug Administration. 2017."},{"key":"10.1016\/j.clinthera.2017.12.018_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.05.018","article-title":"Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care","volume":"263","author":"Guglielmi","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2017.12.018_bib8","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.clinthera.2008.11.012","article-title":"Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel","volume":"30","author":"Chodick","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.12.018_bib9","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2017.12.018_bib10","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/eurheartj\/ehi231","article-title":"Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia","volume":"26","author":"Farnier","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2017.12.018_bib11","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.12.018_bib12","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2017.12.018_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0002-9149(97)00963-6","article-title":"Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction","volume":"81","author":"Schwartz","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2017.12.018_bib14","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2013.10.022","article-title":"Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study","volume":"232","author":"Ballantyne","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.clinthera.2017.12.018_bib15","first-page":"228","article-title":"Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain","volume":"27","author":"Cosin Sales","year":"2015","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.clinthera.2017.12.018_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2006.10.022","article-title":"Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)","volume":"99","author":"Ballantyne","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2017.12.018_bib17","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2017.12.018_bib18","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.clinthera.2004.11.016","volume":"26","author":"Bays","year":"2004","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.12.018_bib19","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jacl.2013.09.009","article-title":"Therapeutic practice patterns related to statin potency and ezetimibe\/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease","volume":"8","author":"Toth","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.clinthera.2017.12.018_bib20","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme","volume":"22","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2017.12.018_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinthera.2007.02.008","article-title":"Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy","volume":"29","author":"Silva","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.12.018_bib22","first-page":"640","article-title":"Statin-induced myositis: a commonly encountered or rare side effect?","volume":"16","author":"Mukhtar","year":"2005","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.clinthera.2017.12.018_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.clinthera.2017.12.018_bib24","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.12.018_bib25","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2017.12.018_bib26","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.12.018_bib27","article-title":"Addition of ezetimibe to statins for patients at high cardiovascular risk: systematic review of patient\u2010important outcomes","author":"Fei","year":"2017","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.clinthera.2017.12.018_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ancard.2014.04.018","article-title":"Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study","volume":"63","author":"Deharo","year":"2014","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"10.1016\/j.clinthera.2017.12.018_bib29","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/1755-5922.12213","article-title":"Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe)","volume":"34","author":"Kim","year":"2016","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2017.12.018_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.clinthera.2016.11.014","article-title":"Combination therapy of rosuvastatin and ezetimibe in patients with high cardiovascular risk","volume":"39","author":"Yang","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.12.018_bib31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.amjcard.2011.03.079","article-title":"Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study)","volume":"108","author":"Bays","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2017.12.018_bib32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2015.7248","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value","volume":"176","author":"Tice","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2017.12.018_bib33","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd1205","article-title":"Rosuvastatin calcium","volume":"2","author":"Quirk","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2017.12.018_bib34","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1185\/030079904125004213","article-title":"Pharmacodynamic interaction between ezetimibe and rosuvastatin","volume":"20","author":"Kosoglou","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.12.018_bib35","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818300079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818300079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T01:11:03Z","timestamp":1538442663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818300079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0149291818300079"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.12.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}